EAHP COVID-19 Resource Centre
The novel coronavirus is rapidly spreading across Europe. Healthcare professionals, such as hospital pharmacists, need to be provided with up-to-date information to adequately manage the situation. EAHP has collected resources that can be used by hospital pharmacists and other healthcare professionals. These range from information provided by specialised agencies, such as the World Health Organisation (WHO) or the European Centre for Disease Prevention and Control (ECDC), to information shared by governments and professional societies in different countries.
Useful resources can be submitted to EAHP via the following email address: covid19[at]eahp[dot]eu
Materials in native languages can be submitted. They should, however, be accompanied by a short English description and a translation of the name of the document into English.
EAHP's COVID-19 Resource Centre offers a structured compilation of scientific and medical knowledge and findings about COVID-19. Its objective is to help hospital pharmacists and other healthcare professionals to identify the most relevant publications on COVID-19 among the large amounts of data generated each day on this subject. This Resource Centre is updated three times per week.
The European Medicines Agency (EMA) is interacting with developers of potential COVID-19 vaccines to enable promising medicines to reach patients as soon as possible. Rolling-reviews - that allow EMA to start assessing data for a promising medicine as soon as they become available - have started for four vaccines out of which two vaccine developers have applied for a conditional marketing authorisation in early December 2020.
WHO has published an array of information about COVID-19 on its website. Information about the outbreak includes but is not limited to country & technical guidance, advice for the public, situation reports and details on global research efforts.
The European Centre for Disease Prevention and Control (ECDC) is monitoring the rapidly evolving situation. Risk assessments, public health guidance and advice on response activities have been provided by the agency. Situation updates, including information on the epidemiological curve and the global distribution, are made available daily.
Apart from ECDC, different other European bodies are providing information about the coronavirus pandemic. The European Medicines Agency (EMA) is contributing to global efforts to save lives during the COVID-19 pandemic by expediting the development and approval of safe and effective treatments and vaccines, supporting the continued availability of medicines in the European Union (EU), and providing reliable information to patients and healthcare professionals. Relevant information is made available by EMA on its dedicated COVID-19 webpage.
In addition to the institutions of the European Union also the Council of Europe is engaged. The European Paediatric Formulary Working Party of the European Directorate for the Quality of Medicines & HealthCare (EDQM) has for example compiled information on products and extemporaneous preparation of paediatric formulations that may be useful in the treatment of COVID-19.
FIP has put together an information hub for pharmacists. Hospital pharmacies in outbreak-affected and unaffected countries have an important role in in-hospital infection control as well as patient care and support. Community pharmacies in coronavirus/COVID-19 (SARS-CoV-2) outbreak-affected and unaffected countries are often the first point of contact with the health system for those with concerns or in need of information and reliable advice. Their responsibilities include stocking appropriate products and promoting disease prevention. Pharmacists may also have roles in clinical laboratories. Guidance is available in several different languages, including Albanian, Chinese, English, French, Polish, Portuguese, Russian, Serbian, Spanish and Turkish.
The health and government officials section of EAHP's COVID-19 Resource Centre contains information shared by European governments as well as their national competent authorities.
Different healthcare professional organisations, including EAHP's own members, have made available a number of valuable resources that are being used by healthcare professionals in their countries. Guidance includes but is not limited to information on the use of personal protective equipment, treatment options and the preparation of disinfectant for hand hygiene.
The patient section of EAHP's resources centre contains information collected by patient associations for patients.
The scientific journal section gathers some of the international multilingual scientific findings and knowledge on COVID-19.
Other useful resource – not falling in one of the above categories – can be found in this section.
Disclaimer for EAHP COVID-19 Resource Centre
All information contained in the EAHP COVID-19 Resource Centre is provided for educational purposes only. This information is not intended to replace clinical judgement or guide individual care in any manner.
The EAHP COVID-19 Resource Centre is intended to serve as a rapidly accessible, concise initial reference resource and not as a complete reference resource. It does not include information concerning every therapeutic agent, laboratory or diagnostic test or procedure available. The Resource Centre is intended to be used only by Users who are: (1) researchers who will not use the information for medical diagnosis or treatment, and (2) other competent healthcare professionals who will rely on their own discretion and judgment in medical diagnosis and treatment.
The User is hereby notified that the information contained herein may not meet the user's needs. The User is advised that, although the information is derived from medical research and literature we cannot guarantee either its correctness, comprehensiveness or currency. The User of this Resource Centre assumes sole responsibility for any decisions made or actions taken based on the information contained in the EAHP COVID-19 Resource Centre.
EAHP shall not be held liable for any special, consequential, or exemplary damages resulting in whole or part from any User's use of or reliance upon the information contained within the Resource Centre.